List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction

    SBC: PHENVOGEN LLC            Topic: 300

    PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Application of PPODA QT for embolization of aneurysms

    SBC: Aneuvas Technologies, Inc.            Topic: 101

    A cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain Often going unnoticed and untreated an aneurysm can cause a sudden and catastrophic hemorrhage or stroke Approximately of patients die from an aneurysm rupture even before receiving medical attention and of patients die despite medical treatment Patients that survive typical ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Oligonucleotide Inhibition for cardiac regeneration in Ischemia

    SBC: Jaan Biotherapeutics LLC            Topic: NHLBI

    PROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTION provided by applicant Pain management is a significant unmet medical need Anandamide is an endocannabinoid mediator that plays important roles in the regulation of pain Previous work has shown that endocannabinoid receptors located outside the central nervous system CNS exert a powerful regulatory control over pain initiation The biological actions of anandamide are stopped by ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of CaSR nutrient therapy for childhood diarrhea

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of the infections causing diarrhea but due to the associated dehydration The pro absorptive Oral Rehydration Solution ORS is the only recommended oral therapy for children with acute diarrhea yet it ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Lead Compound Discovery from Engineered Analogs of Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A novel anti gonorrhea immunotherapeutic

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government